Search

Your search keyword '"Lu, Renhua"' showing total 212 results
Start Over Author "Lu, Renhua"
212 results on '"Lu, Renhua"'

3. Efficacy and safety of compound amino acid capsules in the treatment of malnutrition and calcium and phosphorus metabolism disorders in maintenance hemodialysis patients

Author

WU Wangshu, WANG Minzhou, SONG Ahui, ZHAO Bingru, LU Jiayue, HONG Wenkai, GU Leyi, XIE Kewei, and LU Renhua

Subjects
renal dialysis, malnutrition, calcium metabolism disorder, phosphorus metabolism disorder, compound amino acid capsules, Medicine
Abstract

Objective·To explore the efficacy and safety of compound amino acid capsules in the treatment of malnutrition and calcium and phosphorus metabolism disorders in maintenance hemodialysis patients.Methods·In this prospective, randomized, controlled, single-center study, forty maintenance hemodialysis patients from Renji Hospital, Shanghai Jiao Tong University School of Medicine were randomly divided into two groups, the treatment group (n=21) and the control group (n=19). The treatment group was given oral compound amino acid capsules on the basis of regular hemodialysis treatment, while the control group received no special nutritional intervention. Serum albumin, prealbumin, hemoglobin, ferritin, calcium, phosphorus, 1,25-(OH)2-D3 and intact parathyroid hormone levels were analyzed every 3 months, and the incidence of adverse events including death, cardio-cerebrovascular accidents and vascular access failure was recorded. The total follow-up period was 9 months.Results·Serum albumin and prealbumin in the treatment group at 6-month and 9-month were significantly higher than the baseline parameters (albumin, t=3.574, 5.599, both P

Published
2024
Full Text
View/download PDF

10. DIALIZE China: A Phase IIIb, Randomized, Placebo-Controlled Study to Reduce Predialysis Hyperkalemia With Sodium Zirconium Cyclosilicate in Chinese Patients

Author

Ni, Zhaohui, Lu, Renhua, Xu, Xudong, Bian, Xueyan, Zhou, Zhihong, Yang, Junwei, Luo, Qun, Chen, Menghua, Chen, Chaosheng, Sun, Xiuli, Yu, Lei, He, Qiang, Jiang, Hong, Yuan, Weijie, Li, Yi, Zhou, Rong, Wang, Jianqin, Zhang, Xinzhou, Zuo, Li, Meng, Xiangwen, Chang, Zhiren, Zhao, June, Wessman, Peter, Xiang, Peng, Niu, Jianying, Yan, Tiekun, Ma, Zhigang, Yu, Chen, Cheng, Hong, Zhong, Aimin, Luo, Ping, Wang, Caili, Pai, Pearl, Wang, Zunsong, Wang, Niansong, Liu, Changhua, Xu, Chengyun, Zhang, Rui, Ding, Jiaxiang, Deng, Yueyi, Lu, Jianrao, Wang, Song, Ren, Wei, and Jin, Haijiao

Published
2023
Full Text
View/download PDF

13. Hemodiafiltration with endogenous reinfusion for uremic toxin removal in patients undergoing maintenance hemodialysis: a pilot study.

Author

Lu, Renhua, Fang, Yan, Wu, Wangshu, Zeng, Xiaojun, Liu, Tingting, Qian, Yue, Xie, Yuanyuan, Zhou, Yijun, and Gu, Leyi

Subjects
*HEMODIAFILTRATION, *FIBROBLAST growth factors, *TREATMENT effectiveness, *LEPTIN, *TOXINS, *HIPPURIC acid, *ALBUMINS, *HEMODIALYSIS
Abstract

To delineate the efficacy and safety profile of hemodiafiltration with endogenous reinfusion (HFR) for uremic toxin removal in patients undergoing maintenance hemodialysis (MHD). Patients who have been on MHD for a period of at least 3 months were enrolled. Each subject underwent one HFR and one hemodiafiltration (HDF) treatment. Blood samples were collected before and after a single HFR or HDF treatment to test uremic toxin levels and to calculate clearance rate. The primary efficacy endpoint was to compare uremic toxin levels of indoxyl sulfate (IS), λ-free light chains (λFLC), and β2-microglobulin (β2-MG) before and after HFR treatment. Secondary efficacy endpoints was to compare the levels of urea, interleukin-6 (IL-6), P-cresol, chitinase-3-like protein 1 (YKL-40), leptin (LEP), hippuric acid (HPA), trimethylamine N-oxide (TMAO), asymmetric dimethylarginine (ADMA), tumor necrosis factor-α (TNF-α), fibroblast growth factor 23 (FGF23) before and after HFR treatment. The study also undertook a comparative analysis of uremic toxin clearance between a single HFR and HDF treatment. Meanwhile, the lever of serum albumin and branched-chain amino acids before and after a single HFR or HDF treatment were compared. In terms of safety, the study was meticulous in recording vital signs and the incidence of adverse events throughout its duration. The study enrolled 20 patients. After a single HFR treatment, levels of IS, λFLC, β2-MG, IL-6, P-cresol, YKL-40, LEP, HPA, TMAO, ADMA, TNF-α, and FGF23 significantly decreased (p < 0.001 for all). The clearance rates of λFLC, β2-MG, IL-6, LEP, and TNF-α were significantly higher in HFR compared to HDF (p values: 0.036, 0.042, 0.041, 0.019, and 0.036, respectively). Compared with pre-HFR and post-HFR treatment, levels of serum albumin, valine, and isoleucine showed no significant difference (p > 0.05), while post-HDF, levels of serum albumin significantly decreased (p = 0.000). HFR treatment effectively eliminates uremic toxins from the bloodstream of patients undergoing MHD, especially protein-bound toxins and large middle-molecule toxins. Additionally, it retains essential physiological compounds like albumin and branched-chain amino acids, underscoring its commendable safety profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Assessment of the Prognostic Value of MRI Left Ventricular Global Function Index (LVGFI) in Patients With End‐Stage Renal Disease Under Maintenance Dialysis.

Author

Zhang, Tian‐yi, An, Dong‐aolei, Fang, Yan, Zhou, Hang, Yan, Hao, Chen, Binghua, Lu, Renhua, Fang, Wei, Wang, Qin, Che, Xiajing, Xu, Yao, Huang, Jiaying, Jin, Haijiao, Shen, Jianxiao, Mou, Shan, and Wu, Lian‐Ming

Subjects
CHRONIC kidney failure, PROGNOSIS, MAJOR adverse cardiovascular events, DIALYSIS (Chemistry)
Abstract

Background: Left ventricular global function index (LVGFI) integrates LV volumetric and functional parameters. In patients with end‐stage renal disease (ESRD), cardiac injury manifests as LV hypertrophy and dysfunction. However, the prognostic value of LVGFI in this population remains unclear. Purpose: To investigate the association of LVGFI with major adverse cardiac events (MACE) in patients with ESRD. Study Type: Prospective. Population: One hundred fifty‐eight ESRD patients (mean age: 54.1 ± 14.4 years; 105 male) on maintenance dialysis. Filed Strength/Sequence: 3.0 T, balanced steady‐state free precession (bSSFP) cine and modified Look‐Locker inversion recovery (MOLLI) sequences. Assessment: LV volumetric and functional parameters were determined from bSSFP images. LVGFI was calculated as the ratio of stroke volume to global volume and native T1 was determined from MOLLI T1 maps. MACE was recorded on follow up. Models were developed to predict MACE from conventional risk factors combined with LVGFI, GLS, native T1, and LV mass index (LVMI), respectively. Subgroup analyses were further performed in participants with LVEF above median. Statistical Tests: Cox proportional hazard regression and log‐rank test were used to investigate the association between LVGFI and MACE. The predictive models were evaluated and compared using Harrell's C‐statistics and DeLong tests. A P value <0.05 was considered statistically significant. Results: Thirty‐four MACE occurred during the median follow‐up period of 26 months. The hazard of MACE increased by 114% for each 10% decrease in LVGFI in univariable analysis. The predictive model consisting of LVGFI (C‐statistic: 0.724) had significantly better predictive performance than the others (all P < 0.001). These results were consistent in patients (N = 79) with LVEF > median (63.54%). Data Conclusion: LVGFI is a novel marker for MACE risk stratification in patients with ESRD and was better able to predict MACE than native T1 mapping and GLS. Evidence Level: 2 Technical Efficacy: Stage 3 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Assessment of the Prognostic Value of MRI Left Ventricular Global Function Index (LVGFI) in Patients With End‐Stage Renal Disease Under Maintenance Dialysis

Author

Zhang, Tian‐yi, primary, An, Dong‐aolei, additional, Fang, Yan, additional, Zhou, Hang, additional, Yan, Hao, additional, Chen, Binghua, additional, Lu, Renhua, additional, Fang, Wei, additional, Wang, Qin, additional, Che, Xiajing, additional, Xu, Yao, additional, Huang, Jiaying, additional, Jin, Haijiao, additional, Shen, Jianxiao, additional, Mou, Shan, additional, and Wu, Lian‐Ming, additional

Published
2023
Full Text
View/download PDF

18. Left Ventricular Vertical Run‐Length Nonuniformity MRI Adds Prognostic Value to MACE in Patients with End‐Stage Renal Disease.

Author

Zhang, Tian‐yi, An, Dong‐aolei, Zhou, Hang, Chen, Binghua, Lu, Renhua, Fang, Wei, Wang, Qin, Huang, Jiaying, Jin, Haijiao, Shen, Jianxiao, Zhou, Yin, Hu, Jiani, Bautista, Matthew, Ouchi, Takahiro, Wu, Lian‐Ming, and Mou, Shan

Subjects
CHRONIC kidney failure, PROGNOSIS, MYOCARDIAL infarction, GLOBAL longitudinal strain, ARRHYTHMIA, MAJOR adverse cardiovascular events, CARDIAC magnetic resonance imaging
Abstract

Background: Vertical run‐length nonuniformity (VRLN) is a texture feature representing heterogeneity within native T1 images and reflects the extent of cardiac fibrosis. In uremic cardiomyopathy, interstitial fibrosis was the major histological alteration. The prognostic value of VRLN in patients with end‐stage renal disease (ESRD) remains unclear. Purpose: To evaluate the prognostic value of VRLN MRI in patients with ESRD. Study Type: Prospective. Population: A total of 127 ESRD patients (30 participants in the major adverse cardiac events, MACE group). Field Strength/Sequence: 3.0 T/steady‐state free precession sequence, modified Look‐Locker imaging. Assessment: MRI image qualities were assessed by three independent radiologists. VRLN values were measured in the myocardium on the mid‐ventricular short‐axis slice of T1 mapping. Left ventricular (LV) mass, LV end‐diastolic and end‐systolic volume, as well as LV global strain cardiac parameters were measured. Statistical Tests: The primary endpoint was the incident of MACE from enrollment time to January 2023. MACE is a composite endpoint consisting of all‐cause mortality, acute myocardial infarction, stroke, heart failure hospitalization, and life‐threatening arrhythmia. Cox proportional‐hazards regression was performed to test whether VRLN independently correlated with MACE. The intraclass correlation coefficients of VRLN were calculated to evaluate intraobserver and interobserver reproducibility. The C‐index was computed to examine the prognostic value of VRLN. P‐value <0.05 were considered statistically significant. Results: Participants were followed for a median of 26 months. VRLN, age, LV end‐systolic volume index, and global longitudinal strain remained significantly associated with MACE in the multivariable model. Adding VRLN to a baseline model containing clinical and conventional cardiac MRI parameters significantly improved the accuracy of the predictive model (C‐index of the baseline model: 0.781 vs. the model added VRLN: 0.814). Data Conclusion: VRLN is a novel marker for risk stratification toward MACE in patients with ESRD, superior to native T1 mapping and LV ejection fraction. Evidence Level: 2 Technical Efficacy Stage: 2 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Contributors

Author

Albright, Robert C., primary, Amerling, Richard, additional, Angeli, Paolo, additional, Angelotti, Maria Lucia, additional, Antonelli, Massimo, additional, Antoniotti, Riccardo, additional, Arulkumaran, Nishkantha, additional, Asfar, Pierre, additional, Ash, Stephen R., additional, Aucella, Filippo, additional, Aucella, Francesco, additional, Ave, Samuele, additional, Bagshaw, Sean M., additional, Balaraman, Vasanthi, additional, Baldwin, Ian, additional, Bargman, Joanne M., additional, Barletta, Gina-Marie, additional, Barletta, Jeffrey F., additional, Barnela, Shriganesh R., additional, Bayır, Hülya, additional, Beaulieu, Monica, additional, Bellasi, Antonio, additional, Bellomo, Rinaldo, additional, Beloncle, François, additional, Bhansali, Arjun, additional, Bihorac, Azra, additional, Billings, Frederic T., additional, Birk, Horst-Walter, additional, Bonilla-Reséndiz, Luis Ignacio, additional, Bouchard, Josée, additional, Bourke, Edmund, additional, Braitberg, George, additional, Brendolan, Alessandra, additional, Brocca, Alessandra, additional, Brophy, Patrick D., additional, Bucala, Richard, additional, Bunchman, Timothy E., additional, Burdmann, Emmanuel A., additional, Busse, Laurence W., additional, Caires, Renato Antunes, additional, Caironi, Pietro, additional, Camilla, Roberta, additional, Campos, Israel, additional, Canaud, Bernard, additional, Cantaluppi, Vincenzo, additional, Martinez, Maria P., additional, Capasso, Giovambattista, additional, Carcillo, Joseph A., additional, Carlesso, Eleonora, additional, Casino, Francesco G., additional, Castellano, Giuseppe, additional, Catania, Matteo, additional, Cawcutt, Kelly A., additional, Cerda, Jorge, additional, Charen, Elliot, additional, Chawla, Lakhmir S., additional, Chiaramonte, Stefano, additional, Chua, Horng-Ruey, additional, Cianciaruso, Bruno, additional, Ciceri, Paola, additional, Cieslak, Jacek, additional, Clark, William R., additional, Claure-Del Granado, Rolando, additional, Clementi, Anna, additional, Co, Ivan N., additional, Coelho, Fernanda Oliveira, additional, Conte, Ferruccio, additional, Corey, Howard E., additional, Cosmai, Laura, additional, Costalonga, Elerson Carlos, additional, Costamagna, Andrea, additional, Costanzo, Maria Rosa, additional, Cozzolino, Mario, additional, Cramer, Carl H., additional, Cravedi, Paolo, additional, Crepaldi, Carlo, additional, Creteur, Jacques, additional, Crew, R. John, additional, da Costa e Silva, Verônica Torres, additional, Davenport, Andrew, additional, Davies, Andrew R., additional, D'Costa, Rohit, additional, Dean, Dawson F., additional, Debiais, Charlotte, additional, de Cal, Massimo, additional, Dedhia, Paras, additional, de Grooth, Harm-Jan, additional, Dell'Aquila, Roberto, additional, Dellepiane, Sergio, additional, Dellinger, Richard Phillip, additional, Del Vecchio, Lucia, additional, Depner, Thomas A., additional, De Rosa, Silvia, additional, Deutschman, Clifford S., additional, Devarajan, Prasad, additional, Dewitte, A., additional, Di Iorio, Biagio R., additional, Di Lullo, Luca, additional, Di Micco, Lucia, additional, Di Nardo, Matteo, additional, Ding, Xiaoqiang, additional, D'Ippoliti, Fiorella, additional, Di Somma, Salvatore, additional, Doi, Kent, additional, Dries, David J., additional, Druml, Wilfred, additional, Duke, Graeme, additional, Durand, Francois, additional, Eadon, Michael T., additional, Eckstein, Devin, additional, Egi, Moritoki, additional, Eiam-Ong, Somchai, additional, Elbers, Paul W.G., additional, Elli, Francesca, additional, Elliott, Steve, additional, Emlet, David R., additional, Endre, Zoltan, additional, Evans, Roger G., additional, Fanelli, Vito, additional, Fattahi, Fatemeh, additional, Federspiel, Christine Kinggaard, additional, Ferrada, Marcela A., additional, Ferrari, Fiorenza, additional, Fiaccadori, Enrico, additional, Fiorentino, Marco, additional, Fisher, Caleb, additional, Flessner, Michael F., additional, Formica, Marco, additional, Forni, Lui G., additional, Francoz, Claire, additional, French, Craig, additional, Fuhrman, Dana Y., additional, Fumagalli, Giordano, additional, Galbusera, Miriam, additional, Gallieni, Maurizio, additional, Gammill, Hilary S., additional, Gao, Dayong, additional, Garzotto, Francesco, additional, Gatta, Giuseppe, additional, Genga, Kelly R., additional, Genovesi, Simonetta, additional, Genyk, Yuri S., additional, Geradin, Christel, additional, Gesualdo, Loreto, additional, Giavarina, Davide, additional, Giuliani, Anna, additional, Glezerman, Ilya G., additional, Goldstein, Stuart L., additional, Golper, Thomas A., additional, Gómez, Hernando, additional, Granata, Antonio, additional, Grandaliano, Giuseppe, additional, Grasselli, Giacomo, additional, Groeneveld, A.B. Johan, additional, Guerci, Philippe, additional, Gunnerson, Kyle J., additional, Harbord, Nikolas, additional, Harshman, Lyndsay A., additional, Hennessy, Anthony J., additional, Hill, Graham L., additional, Hobson, Charles, additional, Hohenstein, Bernd, additional, Honoré, Patrick M., additional, Horwitz, Edward, additional, Hosseinian, Leila, additional, Hoste, Eric A.J., additional, House, Andrew A., additional, Humes, H. David, additional, Husain-Syed, Faeq, additional, Ince, Can, additional, Ing, Todd S., additional, Jacobs, Rita, additional, Jaswal, Dharmvir, additional, Jeyabalan, Arun, additional, Joannes-Boyau, Olivier, additional, Joannidis, Michael, additional, Joyce, Emily, additional, Kane-Gill, Sandra L., additional, Kaplan, Lewis J., additional, Kashani, Kianoush, additional, Katz, Nevin, additional, Kellum, John A., additional, Khanna, Ramesh, additional, Kim-Campbell, Nahmah, additional, King, Joshua D., additional, Kirwan, Christopher J., additional, Kiss, Joseph E., additional, Klein, David, additional, Kotanko, Peter, additional, Krediet, Raymond T., additional, Kuhlmann, Martin K., additional, Kuiper, Jan Willem, additional, Lachance, Philippe, additional, Lameire, Norbert, additional, Langer, Thomas, additional, Lankadeva, Yugeesh R., additional, Laurin, Louis-Philippe, additional, Lazzeri, Elena, additional, Leblanc, Martine, additional, Lefebvre, Joannie, additional, Lentini, Paolo, additional, Leray-Moragués, Hélène, additional, Levin, Adeera, additional, Lew, Susie Q., additional, Liapis, Helen, additional, Liu, Kathleen D., additional, Livigni, Sergio, additional, Locatelli, Francesco, additional, Lorenzin, Anna, additional, Lu, Jian-Da, additional, Lu, Renhua, additional, Lysak, Nicholas, additional, Macedo, Etienne, additional, Madan, Niti, additional, Madore, François, additional, Maerz, Linda L., additional, Maiden, Matthew J., additional, Malhotra, Rakesh, additional, Marengo, Marita, additional, Mariano, Filippo, additional, Marik, Paul E., additional, Marini, John J., additional, Marino, Rossella, additional, Marshall, Mark R., additional, Mårtensson, Johan, additional, Matsuura, Ryo, additional, May, Clive N., additional, Mazzone, Patrizio, additional, McCauley, Jerry, additional, McCullough, Peter A., additional, McMahon, Blaithin A., additional, Mehta, Ravindra L., additional, Mele, Caterina, additional, Menon, Madhav, additional, Meola, Mario, additional, Mérouani, Aicha, additional, Meuwly, Jean-Yves, additional, Milla, Paola, additional, Misra, Madhukar, additional, Misra, Paraish S., additional, Mizock, Barry A., additional, Modi, Jwalant R., additional, Moeckel, Gilbert, additional, Molitoris, Bruce A., additional, Morabito, Santo, additional, Mucelli, Roberto Pozzi, additional, Murray, Patrick T., additional, Murugan, Raghavan, additional, Nadim, Mitra K., additional, Nair, Devika, additional, Nalesso, Federico, additional, Neri, Mauro, additional, Nguyen, Trung C., additional, Ni, Zhaohui, additional, Noris, Marina, additional, Novick, Tessa, additional, O'Horo, John C., additional, Okusa, Mark Douglas, additional, Opal, Steven M., additional, Opdam, Helen Ingrid, additional, Ostermann, Marlies, additional, Ottaviano, Emerenziana, additional, Oudemans-van Straaten, Heleen M., additional, Overgaard-Steensen, Christian, additional, Padalino, Massimo A., additional, Panichi, Vincenzo, additional, Parameswaran, Priyanka, additional, Patel, Samir S., additional, Payen, Didier, additional, Pea, Federico, additional, Peacock, W. Frank, additional, Peart, Sandrica Young, additional, Peerapornratana, Sadudee, additional, Pelosi, Paolo, additional, Peng, Zhi-Yong, additional, Perico, Norberto, additional, Peruzzi, Licia, additional, Pesce, Francesco, additional, Pesenti, Antonio, additional, Petrucci, Ilaria, additional, Pham, Phuong-Chi, additional, Pham, Phuong-Thu, additional, Phoon, Richard K.S., additional, Piano, Salvatore, additional, Pinsky, Michael R., additional, Piquilloud, Lise, additional, Pistolesi, Valentina, additional, Plank, Lindsay D., additional, Plötz, Frans B., additional, Podestá, Manuel Alfredo, additional, Porta, Camillo, additional, Pozzato, Marco, additional, Prencipe, Michele, additional, Prowle, John R., additional, Puthucheary, Zudin A., additional, Qu, Lirong, additional, Rachoin, Jean-Sebastien, additional, Radhakrishnan, Jai, additional, Ranieri, V. Marco, additional, Ratanarat, Ranistha, additional, Remuzzi, Giuseppe, additional, Resnick, Shelby, additional, Rewa, Oleksa G., additional, Ricci, Zaccaria, additional, Ridel, Christophe, additional, Rifai, Kinan, additional, Ring, Troels, additional, Rizo-Topete, Lilia M., additional, Roessler, Eric, additional, Romagnani, Paola, additional, Romagnoli, Stefano, additional, Ronco, Claudio, additional, Ronco, Federico, additional, Rosner, Mitchell H., additional, Rossetti, Emanuele, additional, Russell, James A., additional, Saab, Georges, additional, Sabatino, Alice, additional, Saboo, Sonali S., additional, Samoni, Sara, additional, Sappington, Penny Lynn, additional, Sartori, Marco, additional, Savige, Judy, additional, Schena, Francesco Paolo, additional, Schneider, Antoine Guillaume, additional, Schraverus, Pieter, additional, Schulte, Wibke, additional, Segoloni, Giuseppe, additional, Semler, Matthew W., additional, Sharma, Aashish, additional, Shaw, Andrew, additional, Sheth, Naitik, additional, Shukla, Ashutosh, additional, Siddall, Eric C., additional, Sievers, Theodore M., additional, Siew, Edward D., additional, Singbartl, Kai, additional, Singer, Mervyn, additional, Singh, Pooja, additional, Smith, Loren E., additional, Soni, Sachin S., additional, Soto, Mara Serrano, additional, Spapen, Herbert D., additional, Srisawat, Nattachai, additional, Srivastava, Ajay, additional, Stellin, Giovanni, additional, Symons, Jordan M., additional, Szamosfalvi, Balazs, additional, Tai, Kian Bun, additional, Takalkar, Unmesh V., additional, Teitelbaum, Isaac, additional, Tetta, Ciro, additional, Thakar, Charuhas V., additional, Tonon, Marta, additional, Trepiccione, Francesco, additional, Triulzi, Darrell, additional, Tushar, Chopra, additional, Uchino, Shigehiko, additional, Valika, Ali, additional, Van Biesen, Wim, additional, Vandenberghe, Wim, additional, Vanholder, Raymond, additional, Vanmassenhove, Jill, additional, Verbine, Anton, additional, Vergano, Marco, additional, Villa, Gianluca, additional, Villeneuve, Pierre-Marc, additional, Vincent, Jean-Louis, additional, Vinsonneau, Christophe, additional, Virzì, Grazia Maria, additional, Visconti, Federico, additional, Visvanathan, Ravindran, additional, Van Vong, Li, additional, Walmrath, Hans-Dieter, additional, Ward, Peter A., additional, Weir, Matthew A., additional, Wen, Xiaoyan, additional, Wendon, Julia, additional, Winchester, James Frank, additional, Wong, Adrian, additional, Woodhouse, Elke L., additional, Xue, Jun, additional, Yadav, Anju, additional, Yerram, Preethi, additional, Yessayan, Lenar, additional, Yeun, Jane Y., additional, Yu, Alex W., additional, Zaccaria, Marta, additional, Zacchia, Miriam, additional, Zachariah, Teena P., additional, Zamperetti, Nereo, additional, Zampieri, Fernando G., additional, Zanco, Pierluigi, additional, Zanella, Alberto, additional, Zanoli, Luca, additional, Zappitelli, Michael, additional, Zaragoza, Jose J., additional, Zarbock, Alexander, additional, Zaroccolo, Marta, additional, Zhang, Han, additional, and Zimmer, Andrea, additional

Published
2019
Full Text
View/download PDF

21. Left Ventricular Vertical Run‐Length Nonuniformity MRI Adds Prognostic Value to MACE in Patients with End‐Stage Renal Disease

Author

Zhang, Tian‐yi, primary, An, Dong‐aolei, additional, Zhou, Hang, additional, Chen, Binghua, additional, Lu, Renhua, additional, Fang, Wei, additional, Wang, Qin, additional, Huang, Jiaying, additional, Jin, Haijiao, additional, Shen, Jianxiao, additional, Zhou, Yin, additional, Hu, Jiani, additional, Bautista, Matthew, additional, Ouchi, Takahiro, additional, Wu, Lian‐Ming, additional, and Mou, Shan, additional

Published
2023
Full Text
View/download PDF

23. Texture analysis of native T1 images as a novel method for non-invasive assessment of heart failure with preserved ejection fraction in end-stage renal disease patients

Author

Zhang, Tian-yi, primary, An, Dong-aolei, additional, Zhou, Hang, additional, Ni, Zhaohui, additional, Wang, Qin, additional, Chen, Binghua, additional, Lu, Renhua, additional, Huang, Jiaying, additional, Zhou, Yin, additional, Kim, Doo Hee, additional, Wilson, Molly, additional, Wu, Lian-Ming, additional, and Mou, Shan, additional

Published
2022
Full Text
View/download PDF

24. The initial attempt at home hemodialysis in mainland China

Author

Ni, Zhaohui, primary, Zhou, Yijun, additional, Lu, Renhua, additional, Shen, Jianxiao, additional, Gu, Leyi, additional, Mou, Shan, additional, Zhao, Li, additional, Zhang, Haifen, additional, Zhang, Bin, additional, Fang, Yan, additional, Fang, Wei, additional, Wang, Qin, additional, Zhang, WeiMing, additional, Zhang, Jidong, additional, and Li, Weiping, additional

Published
2022
Full Text
View/download PDF

25. Automated peritoneal dialysis as a cost-effective urgent-start dialysis option for ESRD patients: A prospective cohort study

Author

Jin, Haijiao, primary, Lu, Renhua, additional, Lv, Shifan, additional, Wang, Ling, additional, Mou, Shan, additional, Zhang, Minfang, additional, Wang, Qin, additional, Pang, Huihua, additional, Yan, Hao, additional, Li, Zhenyuan, additional, Che, Miaoling, additional, Shen, Jianxiao, additional, Yan, Jiayi, additional, Gu, Aiping, additional, Zhang, Haifen, additional, Liu, Qian, additional, Fang, Nina, additional, Jin, Yan, additional, and Ni, Zhaohui, additional

Published
2022
Full Text
View/download PDF

26. Incremental diagnostic value of CMR-derived LA strain and strain rate in dialysis patients with HFpEF

Author

Zhou, Hang, primary, An, Dong-Aolei, additional, Ni, Zhaohui, additional, Xu, Jianrong, additional, Zhou, Yan, additional, Fang, Wei, additional, Lu, Renhua, additional, Ying, Liang, additional, Huang, Jiaying, additional, Yao, Qiuying, additional, Li, Dawei, additional, Hu, Jiani, additional, Chen, Binghua, additional, Shen, Jianxiao, additional, Jin, Haijiao, additional, Wei, Yuehan, additional, Ouchi, Erika, additional, Xu, Lei, additional, Wu, Lian-Ming, additional, and Mou, Shan, additional

Published
2022
Full Text
View/download PDF

28. Magnetic Resonance Imaging Quantification of Accumulation of Epicardial Adipose Tissue Adds Independent Risks for Diastolic Dysfunction among Dialysis Patients

Author

Zhou, Hang, primary, An, Dong‐Aolei, additional, Ni, Zhaohui, additional, Xu, Jianrong, additional, Zhou, Yan, additional, Fang, Wei, additional, Lu, Renhua, additional, Ying, Liang, additional, Huang, Jiaying, additional, Yao, Qiuying, additional, Li, Dawei, additional, Hu, Jiani, additional, Chen, Binghua, additional, Shen, Jianxiao, additional, Jin, Haijiao, additional, Wei, Yuehan, additional, Fahmy, Lara M., additional, Jing, Du, additional, Ye, Jing, additional, Xu, Lei, additional, Wu, Lian‐Ming, additional, and Mou, Shan, additional

Published
2022
Full Text
View/download PDF

29. Hyperkalaemia prevalence, recurrence and treatment in patients on haemodialysis in China: protocol for a prospective multicentre cohort study (PRECEDE-K)

Author

Ni, Zhaohui, primary, Jin, Haijiao, additional, Lu, Renhua, additional, Zuo, Li, additional, Yu, Weimin, additional, Ren, Yuqing, additional, Yang, Qiongqiong, additional, Xiao, Jie, additional, Zhang, Qinghong, additional, Zhang, Lihong, additional, Zhang, Xinzhou, additional, Chen, Qinkai, additional, Chen, Chaosheng, additional, Shao, Guojian, additional, Luo, Qun, additional, Yao, Li, additional, Qin, Shuguang, additional, Peng, Hui, additional, and Zhao, Qing, additional

Published
2021
Full Text
View/download PDF

30. Protocol for thiamine and folic acid in the treatment of cognitive impairment in maintenance haemodialysis patients: a prospective, randomised, placebo-controlled, double-blind, multicentre study

Author

Lu, Renhua, primary, Gu, Le-Yi, additional, Zhang, Weiming, additional, Guo, Yongping, additional, Zang, Xiujuan, additional, Zhou, Yan, additional, Yu, Ling, additional, Pan, Shuting, additional, Pang, Huihua, additional, Liu, Shang, additional, Xie, Kewei, additional, Li, Ping, additional, Zeng, Xiaojun, additional, and Lu, Yifei, additional

Published
2021
Full Text
View/download PDF

32. Efficacy and safety of polysaccharide iron complex capsules compared with iron sucrose in hemodialysis patients: study protocol for a randomized, open-label, positive control, multicenter trial (IHOPE)

Author

Lu, Renhua, primary, Zhang, Xu, additional, Cai, Xudong, additional, Wang, Xiaoxia, additional, Li, Hua, additional, Wang, Li, additional, Zhou, Yijun, additional, Shen, Jianxiao, additional, Liu, Qian, additional, Zhang, Haifen, additional, and Ni, Zhaohui, additional

Published
2021
Full Text
View/download PDF

35. Intelligent “Internet Plus” services in the first case of home hemodialysis in mainland China

Author

Ni, Zhaohui, primary, Zhou, Yijun, additional, Lu, Renhua, additional, Shen, Jianxiao, additional, Zhao, Li, additional, Jin, Haijiao, additional, Zhang, Haifen, additional, Zhang, Bin, additional, Li, Zhenyuan, additional, Fang, Yan, additional, Fang, Wei, additional, Wang, Qin, additional, Gu, Leyi, additional, Zhang, Weiming, additional, Zhang, Jidong, additional, Mou, Shan, additional, and Li, Weiping, additional

Published
2021
Full Text
View/download PDF

36. Myocardial Iron Deficiency Quantification and Effective Cardiac Iron Management Strategy Exploration evaluated by Cardiac T2* Mapping in End-Stage Renal Disease Patients

Author

Zhou, Hang, primary, Wei, Yuehan, additional, An, Dong-Aolei, additional, Ni, Zhaohui, additional, Xu, Jianrong, additional, Fang, Wei, additional, Lu, Renhua, additional, Ying, Liang, additional, Chen, Binghua, additional, Jin, Haijiao, additional, Huang, Jiaying, additional, Yao, Qiuying, additional, Wesemann, Luke, additional, Wu, Lian-Ming, additional, and Mou, Shan, additional

Published
2021
Full Text
View/download PDF

37. Texture Analysis of Native T1 Images as a Novel Method for Noninvasive Assessment of Uremic Cardiomyopathy

Author

Zhou, Hang, primary, An, Dong‐Aolei, additional, Ni, Zhaohui, additional, Xu, Jianrong, additional, Fang, Wei, additional, Lu, Renhua, additional, Ying, Liang, additional, Huang, Jiaying, additional, Yao, Qiuying, additional, Li, Dawei, additional, Chen, Binghua, additional, Shen, Jianxiao, additional, Jin, Haijiao, additional, Wei, Yuehan, additional, Hu, Jiani, additional, Fahmy, Lara M., additional, Wesemann, Luke, additional, Qi, Shouliang, additional, Wu, Lian‐Ming, additional, and Mou, Shan, additional

Published
2021
Full Text
View/download PDF

39. Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy

Author

Lin, Qisheng, primary, Li, Shu, additional, Jiang, Na, additional, Jin, Haijiao, additional, Shao, Xinghua, additional, Zhu, Xuying, additional, Wu, Jingkui, additional, Zhang, Minfang, additional, Zhang, Zhen, additional, Shen, Jianxiao, additional, Zhou, Wenyan, additional, Gu, Leyi, additional, Lu, Renhua, additional, and Ni, Zhaohui, additional

Published
2020
Full Text
View/download PDF

43. Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy.

Author

Lin, Qisheng, Li, Shu, Jiang, Na, Jin, Haijiao, Shao, Xinghua, Zhu, Xuying, Wu, Jingkui, Zhang, Minfang, Zhang, Zhen, Shen, Jianxiao, Zhou, Wenyan, Gu, Leyi, Lu, Renhua, and Ni, Zhaohui

Subjects
ACUTE kidney failure, NLRP3 protein, INFLAMMASOMES, TUBULINS, SMALL interfering RNA, GENE enhancers
Abstract

The pathogenetic mechanism of contrast-induced acute kidney injury (CI-AKI), which is the third most common cause of hospital-acquired AKI, has not been elucidated. Previously, we demonstrated that renal injury and cell apoptosis were attenuated in nlrp3 knockout CI-AKI mice. Here, we investigated the mechanism underlying NLRP3 inhibition-mediated attenuation of apoptosis in CI-AKI. The RNA sequencing analysis of renal cortex revealed that the nlrp3 or casp1 knockout CI-AKI mice exhibited upregulated cellular response to hypoxia, mitochondrial oxidation, and autophagy when compared with the wild-type (WT) CI-AKI mice, which indicated that NLRP3 inflammasome inhibition resulted in the upregulation of hypoxia signaling pathway and mitophagy. The nlrp3 or casp1 knockout CI-AKI mice and iohexol-treated HK-2 cells with MCC950 pretreatment exhibited upregulated levels of HIF1A, BECN1, BNIP3, and LC3B-II, as well as enhanced colocalization of LC3B with BNIP3 and mitochondria, and colocalization of mitochondria with lysosomes. Additionally, roxadustat, a HIF prolyl-hydroxylase inhibitor, protected the renal tubular epithelial cells against iohexol-induced injury through stabilization of HIF1A and activation of downstream BNIP3-mediated mitophagy in vivo and in vitro. Moreover, BNIP3 deficiency markedly decreased mitophagy, and also significantly exacerbated apoptosis and renal injury. This suggested the protective function of BNIP3-mediated mitophagy in CI-AKI. This study elucidated a novel mechanism in which NLRP3 inflammasome inhibition attenuated apoptosis and upregulated HIF1A and BNIP3-mediated mitophagy in CI-AKI. Additionally, this study demonstrated the potential applications of MCC950 and roxadustat in clinical CI-AKI treatment. Abbreviations: BNIP3: BCL2/adenovirus E1B interacting protein 3; Ctrl: control; DAPI: 4′,6-diamidino-2-phenylindole dihydrochloride; EGLN2/PHD1: egl-9 family hypoxia-inducible factor 2; HIF1A: hypoxia inducible factor 1, alpha subunit; H-E: hematoxylin and eosin; IL18: interleukin 18; IL1B: interleukin 1 beta; LAMP1: lysosomal-associated membrane protein 1; MAP1LC3B/LC3B: microtubule-associated protein 1 light chain 3 beta; mRNA: messenger RNA; NFKB/NF-κB: nuclear factor of kappa light polypeptide gene enhancer in B cells; NLRP3: NLR family, pyrin domain containing 3; NS: normal saline; PRKN/Parkin: parkin RBR E3 ubiquitin protein ligase; PINK1: PTEN induced putative kinase 1; RNA: ribonucleic acid; SEM: standard error of the mean; siRNA: small interfering RNA; TEM: transmission electron microscopy; TUBA/α-tubulin: tubulin, alpha; TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling; VDAC: voltage-dependent anion channel; WT: wild-type [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation

Author

Lin, Qisheng, primary, Li, Shu, additional, Jiang, Na, additional, Shao, Xinghua, additional, Zhang, Minfang, additional, Jin, Haijiao, additional, Zhang, Zhen, additional, Shen, Jianxiao, additional, Zhou, Yijun, additional, Zhou, Wenyan, additional, Gu, Leyi, additional, Lu, Renhua, additional, and Ni, Zhaohui, additional

Published
2019
Full Text
View/download PDF

47. Reduction of mitochondria and up regulation of pyruvate dehydrogenase kinase 4 of skeletal muscle in patients with chronic kidney disease

Author

Xu, Chenqi, primary, Kasimumali, Ayijiaken, additional, Guo, Xiangjiang, additional, Lu, Renhua, additional, Xie, Kewei, additional, Zhu, Mingli, additional, Qian, Yingying, additional, Chen, Xiaohuan, additional, Pang, Huihua, additional, Wang, Qin, additional, Fan, Zhuping, additional, Dai, Huili, additional, Mou, Shan, additional, Ni, Zhaohui, additional, and Gu, Leyi, additional

Published
2019
Full Text
View/download PDF

50. Use of Both Serum Cystatin C and Creatinine as Diagnostic Criteria for Cardiac Surgery-Associated Acute Kidney Injury and Its Correlation with Long-Term Major Adverse Events

Author

Che, Miaolin, primary, Wang, Xudong, additional, Xie, Bo, additional, Huang, Ritai, additional, Liu, Shang, additional, Yan, Yucheng, additional, Zhu, Mingli, additional, Lu, Renhua, additional, Qian, Jiaqi, additional, Zhang, Weiming, additional, Gu, Leyi, additional, Mou, Shan, additional, Ni, Zhaohui, additional, and Xue, Song, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results